BELITE BIO, INC

Analyst Reco. Belite Bio, Inc

Equities

BLTE

US07782B1044

Market Closed - Nasdaq Other stock markets 04:00:01 2024-04-23 pm EDT			5-day change	1st Jan Change
37.31 ^USD	+8.21%		+3.99%	-18.45%

Mar. 22	Belite Bio Completes Regulatory Submission for Tinlarebant's Clinical Trial in Japan	MT
Mar. 22	Belite Bio, Inc Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Maxim Starts Coverage on Belite Bio with Buy Rating, $60 Price Target	Dec. 14	MT
HC Wainwright Raises Price Target on Belite Bio to $59 From $55, Maintains Buy Rating	Nov. 06	MT
Cantor Fitzgerald Initiates Belite Bio at Overweight Rating With $43 Price Target	23-07-28	MT
SVB Securities Starts Belite Bio at Outperform With $25 Price Target	23-07-26	MT
HC Wainwright Adjusts Belite Bio's Price Target to $55 From $58, Keeps Buy Rating	23-06-05	MT
HC Wainwright Initiates Coverage on Belite Bio With Buy Rating, $58 Price Target	22-08-01	MT
Benchmark Capital Initiates Belite Bio at Buy with $57 Price Target	22-07-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer